AndhraNews.net
Home » Business News » 2014 » May » May 5, 2014

Management Change at Actelion - Roland Haefeli to focus on senior advisory role - Andrew Weiss new Head of Investor Relations and Corporate Communications


May 5, 2014 - London

Actelion Pharmaceuticals Ltd /Management Change at Actelion - Roland Haefeli to focus on senior advisory role - Andrew Weiss new Head of Investor Relations and Corporate Communications . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

ALLSCHWIL/BASEL, SWITZERLAND - 05 May 2014 - Actelion Ltd (SIX: ATLN) today announced that Roland Haefeli, Senior Vice President, Head of Investor Relations and Public Affairs (IR & PA) and member of the Extended Actelion Executive Committee (AEC) has decided to step down from his current role for personal reasons effective 05 May 2014. Roland Haefeli will stay with Actelion in a senior advisory role. 

Roland will hand over his position to Andrew Weiss, who joins Actelion from Bank Vontobel, where he was Head of Life Science Equity Research / Pharma Analyst.

Jean-Paul Clozel M.D. and Chief Executive Officer commented: "I am very pleased to welcome Andrew Weiss to Actelion as new Head of IR & CC and member of the Extended AEC. He brings an excellent understanding of the pharmaceutical market and a deep experience of the financial community. I am convinced that with his background and skills he will contribute to the future success of Actelion."

Jean-Paul Clozel added: "Roland Haefeli has been with Actelion for more than 13 years, and has contributed significantly to our success. As Head of IR & PA he tirelessly managed all communication with the financial community and media in order to achieve a fair valuation of Actelion. I am grateful that he will continue to share his know-how and stay in a senior advisory role at Actelion as I immensely value his advice, his enthusiasm and commitment to our company."

Jean-Paul Clozel concluded: "This is a very exciting time for Actelion, with recent product launches and our promising late stage pipeline. More than ever, it is important that our strategy and growth opportunities are fully understood and communication with our key stakeholders will play a crucial role in this."

 

###

NOTES TO THE EDITOR 


ABOUT ANDREW WEISS

Andrew Weiss, a Swiss citizen, has a MA degree in Business Administration, Monetary Economics, and Corporate Law from the University of Zurich and is a Chartered Financial Analyst (CFA).

Prior to joining Actelion he was the team leader for Life Sciences Equity Research and a financial analyst covering Swiss/European pharmaceutical/ biotechnology stocks at Bank Vontobel. Before joining Bank Vontobel seven years ago, he worked as an analyst for European Pharmaceuticals at Warburg Dillon Read and as an analyst/fund manager at Julius Baer. Over the past 17 years in the banking sector, he has accumulated a vast knowledge of the pharmaceutical and biotech market.

ABOUT ROLAND HAEFELI

Roland Haefeli, a historian and political economist with advanced degrees from the University of Bern (Switzerland) and UNC Chapel Hill (USA), joined Actelion in 2001 and became Senior Vice-President, Head Investor Relations and Public Affairs, and a member of the Extended Actelion Executive Committee. He started his career in the pharmaceutical industry as a corporate spokesperson for F. Hoffmann-La Roche Ltd.

He also worked as head of media relations for other companies, including Serono. In his early career, a stock market training program in a Swiss Private Bank was followed by several years as a news writer, presenter, and editor for several print and electronic media operations. He also served two years as a Delegate for the International Committee of the Red Cross (ICRC) in Bosnia and Rwanda.

ABOUT ACTELION LTD.

Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs.

Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides in patients with cutaneous T-cell lymphoma.

Founded in late 1997, with now over 2,400 dedicated professionals covering all key markets around the world including the US, Japan, China, Russia and Mexico, Actelion has its corporate headquarters in Allschwil / Basel, Switzerland.

Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All trademarks are legally protected.

 

For further information please contact:

Andrew Jones
Director, Corporate Communications
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
www.actelion.com


Press Release PDF



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Globenewswire

HUG#1782411

GlobeNewswire

Comment on this story

Share